Skip to main content Accessibility help
×
Home

Drug and alcohol addiction: new pharmacotherapies

  • Jason Luty

Summary

Over the past decade, important research has been performed into the therapeutic use of dihydrocodeine, injectable opioids (diamorphine) and supervised disulfiram in addiction treatment. There have also been interesting developments regarding baclofen for alcohol problems and use of stimulants in adult Attention-deficit hyperactivity disorder (ADHD). However, evidence for the effectiveness of medication to promote alcohol abstinence remains modest at best.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Drug and alcohol addiction: new pharmacotherapies
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Drug and alcohol addiction: new pharmacotherapies
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Drug and alcohol addiction: new pharmacotherapies
      Available formats
      ×

Copyright

Corresponding author

Dr Jason Luty, Borders Addiction Service, The Range, Tweed Road, Galashiels TD1 3EB, Scotland. Email: jason.luty@yahoo.co.uk

Footnotes

Hide All

Learning Objectives

Develop awareness of risks of diversion when considering prescribing drugs of misuse such as stimulants for ADHD, morphine and injectables to treat addiction Update information on newer treatments of opioid dependence, especially the buprenorphinenaloxone combination Refresh information on treatment of alcohol misuse and dependence, especially supervised disulfiram and opioid antagonists

Declaration of Interest

None

Footnotes

References

Hide All
Addolorato, G, Leggio, L, Ferrulli, A et al (2007) Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet, 370: 1915–22.
Anton, RF, O'Malley, SS, Ciraulo, DA et al (2006) Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study. A randomized controlled trial. JAMA, 295: 2003–17.
Beck, T, Haasen, C, Verthein, U et al (2014) Maintenance treatment for opioid dependence with slow-release oral morphine: a randomized crossover, non-inferiority study versus methadone. Addiction, 109: 617–26.
Beer, B, Rabl, W, Libiseller, K et al (2010) [Impact of slow-release oral morphine on drug abusing habits in Austria] [article in German]. Neuropsychiatry, 24: 108–17.
Bouza, C, Angeles, M, Muñoz, A et al (2004) Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review. Addiction, 99: 811–28.
Byford, S, Barrett, B, Metrebian, N et al (2013) Cost-effectiveness of injectable opioid treatment v. oral methadone for chronic heroin addiction. British Journal of Psychiatry, 203: 341–9.
Chick, J, Gough, K, Falowski, W et al (1992) Disulfiram treatment of alcoholism. British Journal of Psychiatry, 161: 84–9.
Comer, SD, Sullivan, MA, Yu, E et al (2006) Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomised, placebo-controlled trial. Archives of General Psychiatry, 63: 210–8.
Davoli, M, Bargagli, AM, Perucci, CA et al (2007) Risk of fatal overdose during and after specialist drug treatment: the VEdeTTE study, a national multi-site prospective cohort study. Addiction, 102: 1954–9.
Department of Health (England) and the devolved administrations (2007) Drug Misuse and Dependence: UK Guidelines on Clinical Management. Department of Health (England), Scottish Government, Welsh Assembly Government and Northern Ireland Executive.
de Sousa, A, De Sousa, A (2004) A one-year pragmatic trial of naltrexone vs disulfiram in the treatment of alcohol dependence. Alcohol and Alcoholism, 39: 528–31.
de Sousa, A, De Sousa, A (2005) An open randomized study comparing disulfiram and acamprosate in the treatment of alcohol dependence. Alcohol and Alcoholism, 40: 545–8.
Eder, H, Jagsch, R, Kraigher, D et al (2005) Comparative study of the effectiveness of slow-release morphine and methadone for opioid maintenance therapy. Addiction, 100: 1101–9.
Ferri, M, Minozzi, S, Bo, A et al (2013) Slow-release oral morphine as maintenance therapy for opioid dependence. Cochrane Database of Systematic Reviews, 6: CD009879.
Fiellin, DA, Pantalon, MV, Chawarski, MC et al (2006) Counseling plus buprenorphine–naloxone maintenance therapy for opioid dependence. New England Journal of Medicine, 355: 365–74.
Garbutt, JC, Kampov-Polevoy, AB, Gallop, R et al (2010) Efficacy and safety of baclofen for alcohol dependence: a randomized, double-blind, placebo-controlled trial. Alcoholism: Clinical and Experimental Research, 34: 1849–57.
Hser, YI, Saxon, AJ, Huang, D et al (2013) Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial. Addiction, 109: 7987.
Hughes, JC, Cook, CC (1997) The efficacy of disulfiram: a review of outcome studies. Addiction, 92: 381–95.
Hulse, GK, Morris, N, Arnold-Reed, D et al (2009) Improving clinical outcomes in treating heroin dependence: randomized, controlled trial of oral or implant naltrexone. Archives of General Psychiatry, 66: 1108–15.
Joint Formulary Committee (2014) British National Formulary (68). BMJ Group & Pharmaceutical Press.
Johnsen, J, M⊘rland, J (1991) Disulfiram implant: a double-blind placebo controlled follow-up on treatment outcome. Alcoholism, Clinical and Experimental Research, 15: 532–6.
Kakko, J, Grönbladh, L, Svanborg, KD et al (2007) A stepped care strategy using buprenorphine and methadone versus conventional methadone maintenance in heroin dependence: a randomized controlled trial. American Journal of Psychiatry, 164: 797803.
Koesters, M, Becker, T, Killian, R (2009) Limits of meta-analysis: methylphenidate in the treatment of adult ADHD. Psychiatric Clinics of North America, 23: 733–44.
Konstenius, M, Jayaram-Lindström, N, Guterstam, J et al (2014) Methylphenidate for attention deficit hyperactivity disorder and drug relapse in criminal offenders with substance dependence: a 24-week randomized placebo-controlled trial. Addiction, 109: 440–9.
Krampe, H, Ehrenreich, H (2010) Supervised disulfiram as adjunct to psychotherapy in alcoholism treatment. Current Pharmaceutical Design, 16: 2076–90.
Lobmaier, P, Kornor, H, Kunoe, N et al (2008) Sustained-release naltrexone for opioid dependence. Cochrane Database of Systematic Reviews, 2: CD006140.
Luty, J (2003) What works in drug addiction? Advances in Psychiatric Treatment, 9: 280–8.
Luty, J (2006) What works in alcohol use disorders? Advances in Psychiatric Treatment, 12: 1322.
Luty, J (2014) Drug and alcohol addiction: new challenges. Advances in Psychiatric Treatment, 20: 413–21.
Magon, R, Müller, U (2012) ADHD with comorbid substance use disorder: review of treatment. Advances in Psychiatric Treatment, 18: 436–46.
Mann, K, Lehert, P, Morgan, MY (2004) The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: results of a meta-analysis. Alcoholism: Clinical and Experimental Research, 28: 5163.
Mann, K, Bladström, A, Torup, L et al (2013) Extending the treatment of options in alcohol dependence: a randomized controlled study of as-needed nalmefene. Biological Psychiatry, 73: 706–13.
Mason, BJ, Salvato, FR, Williams, LD (1999) A double-blind placebo controlled study of oral nalmefene for alcohol dependence. Archives of General Psychiatry, 56: 719–24.
Mattick, R P., Kimber, J, Breen, C et al (2008) Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database of Systematic Reviews, 2: CD002207.
Miles, SW, Sheridan, J, Russell, B et al (2013) Extended-release methylphenidate for treatment of amphetamine/methamphetamine dependence: a randomized, double-blind, placebo-controlled trial. Addiction, 108: 1279–86.
Minozzi, S1, Amato, L, Vecchi, S et al (2011) Oral naltrexone maintenance treatment for opioid dependence. Cochrane Database of Systematic Reviews, 4: CD001333.
National Institute for Health and Clinical Excellence (2008) Attention Deficit Hyperactivity Disorder: Diagnosis and Management of ADHD in Children, Young People and Adults (NICE Clinical Guideline 72). NICE.
National Treatment Agency for Substance Misuse (2003) Injectable Heroin (and Injectable Methadone): Potential Roles in Drug Treatment. Full Guidance Report. National Treatment Agency.
Nutt, DJ, Fone, K, Asherson, P et al (2007) Evidence-based guidelines for management of attention-deficit/hyperactivity disorder in adolescents in transition to adult services and in adults: recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology, 21: 1041.
Pani, PP1, Trogu, E, Vacca, R et al (2010) Disulfiram for the treatment of cocaine dependence. Cochrane Database of Systematic Reviews, 1: CD007024.
Pinto, H, Maskrey, V, Swift, L et al (2010) The SUMMIT Trial: a field comparison of buprenorphine versus methadone maintenance treatment. Journal of Substance Abuse Treatment, 39: 340–52.
Raistrick, D, West, D, Finnegan, O et al (2005) A comparison of buprenorphine and lofexidine for community opiate detoxification: results from a randomized controlled trial. Addiction, 100: 1860–7.
Robertson, JR, Raab, GM, Bruce, M et al (2006) Addressing the efficacy of dihydrocodeine versus methadone as an alternative maintenance treatment for opiate dependence: a randomized controlled trial. Addiction, 101: 1752–9.
Rösner, S, Hackl-Herrwerth, A, Leucht, S et al (2010) Naltrexone and nalmefene for alcohol dependent patients. Cochrane Database of Systematic Reviews, 12: CD001867.
Rösner, S, Hackl-Herrwerth, A, Leucht, S et al (2011) Acamprosate for alcohol dependent patients. Cochrane Database of Systematic Reviews, 9: CD004332.
Strang, J, Metrebian, N, Lintzeris, N et al (2010) Supervised injectable heroin or injectable methadone versus optimised oral methadone as treatment for chronic heroin addicts in England after persistent failure in orthodox treatment (RIOTT): a randomised trial. Lancet, 375: 1885–95.
Suh, JJ, Pettinati, HM, Kampman, KM et al (2006) The status of disulfiram: a half of a century later. Journal of Clinical Psychopharmacology, 26: 290302.
Wilens, TE, Adler, LA, Adams, J et al (2008) Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature. Journal of the American Academy of Child & Adolescent Psychiatry, 47: 2131.
Winstock, AR, Lea, T, Sheridan, J (2008) Prevalence of diversion and injection of methadone and buprenorphine among clients receiving opioid treatment at community pharmacies in New South Wales, Australia. International Journal of Drug Policy, 19: 450–8.

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed

Drug and alcohol addiction: new pharmacotherapies

  • Jason Luty
Submit a response

eLetters

No eLetters have been published for this article.

×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *